Incontinence Drug Toviaz Performs Well in Elderly Patients
Dec 7, 2011
There’s reassuring news for those who are among the 33 million Americans with overactive bladder: the prescription drug Toviaz (fesoterodine) performed well in a new double-blind, placebo-controlled trial of 562 elderly men and women with overactive bladder. According to Pfizer Inc., which makes Toviaz, the drug was better than placebo in reducing the number of urinary incontinence episodes participants had each day.
The results of the 12-week trial are particularly important because it is the first study of an antimuscarinic agent (one that blocks the activity of the neurotransmitter acetylcholine) shown to be effective in treating older adults, for whom overactive bladder is especially troublesome and can be debilitating. Overactive bladder is a type of urinary incontinence that can be treated with a variety of medications, including Toviaz, as well as herbal and natural remedies, nerve stimulation, behavioral therapy, Kegel exercises, continence products, and surgery.